-
公开(公告)号：US20180344660A1
公开(公告)日：2018-12-06
申请号：US15757899
申请日：2016-09-08
申请人： GW Pharma Limited
发明人： Philip Robson , Geoffrey Guy , Stephen Wright , Emma Cheetham , Dominic Schiller
IPC分类号： A61K31/05 , A61K31/496 , A61K31/5513 , A61K31/554 , A61K31/519 , A61K31/40 , A61P25/18
CPC分类号： A61K31/05 , A61K31/40 , A61K31/496 , A61K31/519 , A61K31/551 , A61K31/5513 , A61K31/554 , A61P25/18 , A61K2300/00
摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.
-
公开(公告)号：US09949936B2
公开(公告)日：2018-04-24
申请号：US15284766
申请日：2016-10-04
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Charuta Joshi , Angus Wilfong
IPC分类号： A61K31/05 , A61K31/551 , A61K36/185 , A61K31/4015 , A61K31/444 , A61K31/515 , A61K31/4166 , A61K31/55 , A61K31/27 , A61K31/53 , A61K31/19 , A61K9/00 , A61K9/08
CPC分类号： A61K31/05 , A61K9/0053 , A61K9/08 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/197 , A61K31/20 , A61K31/27 , A61K31/35 , A61K31/352 , A61K31/36 , A61K31/4015 , A61K31/4166 , A61K31/423 , A61K31/444 , A61K31/496 , A61K31/515 , A61K31/53 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61K31/7048 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US20170173043A1
公开(公告)日：2017-06-22
申请号：US15449124
申请日：2017-03-03
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/5513 , A61K31/05
CPC分类号： A61K31/05 , A61K9/0053 , A61K9/08 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/197 , A61K31/20 , A61K31/27 , A61K31/35 , A61K31/352 , A61K31/36 , A61K31/4015 , A61K31/4166 , A61K31/423 , A61K31/444 , A61K31/496 , A61K31/515 , A61K31/53 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61K31/7048 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US20170172940A1
公开(公告)日：2017-06-22
申请号：US15449204
申请日：2017-03-03
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/05 , A61K31/352
CPC分类号： A61K31/05 , A61K9/0053 , A61K9/08 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/197 , A61K31/20 , A61K31/27 , A61K31/35 , A61K31/352 , A61K31/36 , A61K31/4015 , A61K31/4166 , A61K31/423 , A61K31/444 , A61K31/496 , A61K31/515 , A61K31/53 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61K31/7048 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US09522123B2
公开(公告)日：2016-12-20
申请号：US14579061
申请日：2014-12-22
发明人： Benjamin Whalley , Gary Stephens , Claire Williams , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
IPC分类号： A61K31/06 , A61K31/352 , A61K31/05
CPC分类号： A61K31/05 , A61K31/352
摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
-
公开(公告)号：US20150086653A1
公开(公告)日：2015-03-26
申请号：US14260876
申请日：2014-04-24
发明人： Daniela Parolaro , Paola Massi , Angelo Antonio Izzo , Francesca Borelli , Gabriella Aviello , Vincenzo Di Marzo , Luciano De Petrocellis , Aniello Schiano Moriello , Alessia Ligresti , Ruth Alexandra Ross , Lesley Ann Ford , Sharon Anavi-Goffer , Manuel Guzman , Guillermo Velasco , Mar Lorente , Sofia Torres , Tetsuro Kikuchi , Geoffrey Guy , Colin Stott , Stephen Wright , Alan Sutton , David Potter , Etienne De Meijer
IPC分类号： A61K36/185 , A61K31/352 , A61K31/015 , A61K31/05 , A61K31/01
CPC分类号： A61K36/185 , A61K31/01 , A61K31/015 , A61K31/05 , A61K31/192 , A61K31/337 , A61K31/352 , A61K31/495 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
摘要翻译： 本发明涉及在治疗癌症中以分离形式或以植物药物物质（BDS）的形式使用植物大麻素。 优选地，待治疗的癌症是前列腺癌，乳腺癌或结肠癌。
-
公开(公告)号：US11311498B2
公开(公告)日：2022-04-26
申请号：US14741829
申请日：2015-06-17
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Orrin Devinsky
IPC分类号： A61K31/05 , A61K31/352 , A61K31/19 , A61K31/5513 , A61K31/195 , A61K31/20 , A61K31/27 , A61K31/4015 , A61K31/4166 , A61K31/423 , A61K31/496 , A61K31/53 , A61K31/551 , A61K31/5517 , A61K31/7048 , A61K36/185 , A61K45/06 , A61K31/165 , A61K31/197 , A61K31/35 , A61K31/36 , A61K47/10 , A61K47/26 , A61K47/44 , A61K9/00 , A61K9/08 , A61K31/444 , A61K31/515 , A61K31/55
摘要： The present disclosure relates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q; Jeavons syndrome; Myoclonic Absence Epilepsy; Neuronal ceroid lipofuscinoses (NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US20200206184A1
公开(公告)日：2020-07-02
申请号：US16562515
申请日：2019-09-06
申请人： GW Pharma Limited
发明人： PHILIP ROBSON , Geoffrey Guy
IPC分类号： A61K31/352 , A61K31/047 , A61K9/00 , A61K31/05 , A61K36/185 , A61K47/10
摘要： The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
-
公开(公告)号：US10653641B2
公开(公告)日：2020-05-19
申请号：US15757899
申请日：2016-09-08
申请人： GW Pharma Limited
发明人： Philip Robson , Geoffrey Guy , Stephen Wright , Emma Cheetham , Dominic Schiller
IPC分类号： A61K31/05 , A61P25/18 , A61K31/496 , A61K31/551 , A61K31/5513 , A61K31/40 , A61K31/519 , A61K31/554
摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.
-
公开(公告)号：US20180338931A1
公开(公告)日：2018-11-29
申请号：US15948412
申请日：2018-04-09
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/05 , A61K31/515 , A61K31/444 , A61K9/00 , A61K31/7048 , A61K31/5517 , A61K31/5513 , A61K31/551 , A61K31/53 , A61K31/496 , A61K31/423 , A61K31/4166 , A61K31/4015 , A61K9/08 , A61K31/55 , A61K47/44 , A61K47/10 , A61K47/26 , A61K31/165 , A61K31/19 , A61K31/197 , A61K31/35 , A61K31/36 , A61K45/06 , A61K36/185 , A61K31/195 , A61K31/20 , A61K31/27 , A61K31/352
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.019 秒)
